Amplia Therapeutics Ltd - Amplia Therapeutics Undertakes Placement
Amplia Therapeutics Ltd (ASX:ATX)

Amplia Therapeutics Undertakes Placement


What's happened?

Amplia Therapeutics Limtied (ASX:ATX) have undertaken a capital raising.

What are the key highlights?

  1. $0.93 million raised.
  2. Platinum International Healthcare Fund participated in the placement which was managed by Taylor Collison.
  3. The new capital will enable the Company to complete the clinic-enabling studies. The Company remains on track to initiate clinical trials of its lead FAK inhibitor, AMP945, during 2020.

CEO's Summary

John Lambert

"We are delighted to have completed this placement as it will allow us to drive our FAK assets into the clinic. We are particularly pleased to see the participation in the placement of such highly regarded investors as Platinum and see this as a strong endorsement of the potential of Amplia’s FAK assets and the team we have put in place."

John Lambert
CEO, Amplia Therapeutics Ltd

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.